Literature DB >> 18057989

Lateral lymph node metastasis is a major cause of locoregional recurrence in rectal cancer treated with preoperative chemoradiotherapy and curative resection.

Tae Hyun Kim1, Seung-Yong Jeong, Dong Hyun Choi, Dae Yong Kim, Kyung Hae Jung, Sung Ho Moon, Hee Jin Chang, Seok-Byung Lim, Hyo Seong Choi, Jae-Gahb Park.   

Abstract

BACKGROUND: In rectal cancer patients treated with preoperative chemoradiotherapy (CRT) and curative resection, we evaluated the effect of clinical parameters on lateral pelvic recurrence and made an attempt to identify a risk factor for lateral pelvic recurrence.
METHODS: The study involved 366 patients who underwent preoperative CRT and curative resection between October 2001 and December 2005. Clinical parameters such as gender, age, tumor size, histologic type, cT and cN classification, ypT and ypN classification, circumferential resection margin, tumor regression grade, chemotherapeutic regimen, and lateral lymph node size were analyzed to identify risk factors associated with lateral pelvic recurrence.
RESULTS: Of the 366 patients, 29 patients (7.9%) had locoregional recurrence: 6 (20.7%) with central pelvic recurrence and 24 (82.7%) had lateral pelvic recurrence, of which 1 had simultaneous central and lateral pelvic recurrence. Multivariate analysis showed that ypN classification and lateral lymph node size were significantly associated with lateral pelvic recurrence (P < .001). Of 250 ypN0 patients, lateral pelvic recurrence developed in 1.4%, 2.9%, and 50% of patients with lateral lymph node sizes of < 5, 5-9.9, and > or = 10 mm, respectively (P < .001). Of 116 ypN+ patients, lateral pelvic recurrence developed in 4.3%, 35.7%, and 87.5% of patients with lateral lymph node sizes of < 5, 5-9.9, and > or = 10 mm, respectively (P < .001).
CONCLUSIONS: In our study, lateral pelvic recurrence was a major cause of locoregional recurrence, and ypN+ and lateral lymph node size were risk factors for lateral pelvic recurrence.

Entities:  

Mesh:

Year:  2007        PMID: 18057989     DOI: 10.1245/s10434-007-9696-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  96 in total

Review 1.  Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis.

Authors:  Irshad Shaikh; Alan Askari; Suzana Ourû; Janindra Warusavitarne; Thanos Athanasiou; Omar Faiz
Journal:  Int J Colorectal Dis       Date:  2014-11-04       Impact factor: 2.571

2.  Is lateral pelvic lymph node dissection no longer necessary for low rectal cancer after neoadjuvant therapy and TME to reduce local recurrence?

Authors:  Takashi Akiyoshi; Toshiaki Watanabe; Masashi Ueno
Journal:  J Gastrointest Surg       Date:  2012-07-06       Impact factor: 3.452

3.  Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients.

Authors:  Tae Gyu Kim; Won Park; Doo Ho Choi; Hee Chul Park; Seok-Hyung Kim; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Woo Yong Lee; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Ho-Kyung Chun
Journal:  Int J Colorectal Dis       Date:  2013-12-10       Impact factor: 2.571

4.  Clinical implication of additional selective lateral lymph node excision in patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy.

Authors:  Seok-Byung Lim; Chang Sik Yu; Chan Wook Kim; Yong Sik Yoon; Seong Ho Park; Tae Won Kim; Jong Hoon Kim; Jin Cheon Kim
Journal:  Int J Colorectal Dis       Date:  2013-08-14       Impact factor: 2.571

5.  Diagnostic value of FDG-PET/CT for lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy.

Authors:  S Ishihara; K Kawai; T Tanaka; T Kiyomatsu; K Hata; H Nozawa; T Morikawa; T Watanabe
Journal:  Tech Coloproctol       Date:  2018-04-06       Impact factor: 3.781

6.  Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

Authors:  Atsushi Ogura; Tsuyoshi Konishi; Chris Cunningham; Julio Garcia-Aguilar; Henrik Iversen; Shigeo Toda; In Kyu Lee; Hong Xiang Lee; Keisuke Uehara; Peter Lee; Hein Putter; Cornelis J H van de Velde; Geerard L Beets; Harm J T Rutten; Miranda Kusters
Journal:  J Clin Oncol       Date:  2018-11-07       Impact factor: 44.544

7.  Incidence and Predictive Model for Lateral Pelvic Lymph Node Metastasis in Lower Rectal Cancer.

Authors:  Kapil Dev; K V Veerenderkumar; Swamyvelu Krishnamurthy
Journal:  Indian J Surg Oncol       Date:  2018-02-04

8.  Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.

Authors:  Ryuichiro Sawada; Takashi Akiyoshi; Yusuke Kitagawa; Yukiharu Hiyoshi; Toshiki Mukai; Toshiya Nagasaki; Tomohiro Yamaguchi; Tsuyoshi Konishi; Noriko Yamamoto; Masashi Ueno; Yosuke Fukunaga
Journal:  Ann Surg Oncol       Date:  2021-04-19       Impact factor: 5.344

9.  Robotic and laparoscopic pelvic lymph node dissection for rectal cancer: short-term outcomes of 21 consecutive series.

Authors:  Sung Uk Bae; Avanish P Saklani; Hyuk Hur; Byung Soh Min; Seung Hyuk Baik; Kang Young Lee; Nam Kyu Kim
Journal:  Ann Surg Treat Res       Date:  2014-01-22       Impact factor: 1.859

10.  Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective.

Authors:  Seo Hee Choi; Jee Suk Chang; Hong In Yoon; Dong-Su Jang; Nam Kyu Kim; Joon Seok Lim; Byung So Min; Hyuk Huh; Sang Joon Shin; Joong Bae Ahn; Woong Sub Koom
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.